106 related articles for article (PubMed ID: 198381)
1. Comparative studies on immunity to EBV-associated antigens in NPC patients in North America, Tunisia, France and Hong Kong.
Levine PH; Wallen WC; Ablashi DV; Granlund DJ; Connelly R
Int J Cancer; 1977 Sep; 20(3):332-8. PubMed ID: 198381
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to Epstein-Barr virus capsid antigen and early antigen in nasopharyngeal carcinoma and comparison groups.
Lin TM; Yang CS; Chiou JF; Tu SM; Chen TY; Tu YC; Lin PJ; Kawamura A; Hirayama T
Am J Epidemiol; 1977 Oct; 106(4):336-9. PubMed ID: 199059
[TBL] [Abstract][Full Text] [Related]
3. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
[TBL] [Abstract][Full Text] [Related]
4. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
[TBL] [Abstract][Full Text] [Related]
5. Cold lymphocytotoxic antibodies in nasopharyngeal carcinoma.
Lamelin JP; Revillard JP; Chalopin JM; Ho JH; Souissi T; Schwaab G; De-Thé G
Br J Cancer; 1977 Apr; 35(4):426-32. PubMed ID: 192260
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the prognostic value of antibody-dependent lymphocyte cytotoxicity and other EBV antibody assays in Chinese patients with nasopharyngeal carcinoma.
Chan SH; Levine PH; de-Thé GB; Mulroney SE; Lavoue MF; Glen SP; Goh EH; Khor TH; Connelly RR
Int J Cancer; 1979 Feb; 23(2):181-5. PubMed ID: 216639
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing EBV-specific IgA in throat washings of nasopharyngeal carcinoma (NPC) patients.
Desgranges C; De-Thé G; Ho JH; Ellouz R
Int J Cancer; 1977 May; 19(5):627-33. PubMed ID: 193801
[TBL] [Abstract][Full Text] [Related]
8. Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other ebv antigens in chinese patients.
de-Thé G; Ho JH; Ablashi DV; Day NE; Macario AJ; Martin-Berthelon MC; Pearson G; Sohier R
Int J Cancer; 1975 Nov; 16(5):713-21. PubMed ID: 171226
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
[TBL] [Abstract][Full Text] [Related]
10. Differences in EBV antibody titres of patients with nasopharyngeal carcinoma originating from high, intermediate and low incidence areas.
de-The G; Lavoue MF; Muenz L
IARC Sci Publ (1971); 1978; (20):471-81. PubMed ID: 215529
[TBL] [Abstract][Full Text] [Related]
11. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
12. Titers of Epstein-Barr virus-related antibodies in nasopharyngeal carcinoma in Japan.
Tamada A; Makimoto K; Yamabe H; Imai J; Hinuma Y; Oyagi A; Araki T
Cancer; 1984 Feb; 53(3):430-40. PubMed ID: 6318948
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of IgA specific antibodies to Epstein-Barr virus capsid and early antigens in nasopharyngeal carcinoma.
Puthavathana P; Kositanont U; Chongkolwatana C; Metheetrairut C; Chantarakul N; Nuntarakchaikul S; Wasi C
Asian Pac J Allergy Immunol; 1993 Jun; 11(1):39-43. PubMed ID: 8216557
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma.
Henle G; Henle W
Int J Cancer; 1976 Jan; 17(1):1-7. PubMed ID: 175020
[TBL] [Abstract][Full Text] [Related]
15. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
[TBL] [Abstract][Full Text] [Related]
16. Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma.
Liu MY; Huang YT; Sheen TS; Chen JY; Tsai CH
J Med Virol; 2004 Aug; 73(4):574-82. PubMed ID: 15221902
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
Dardari R; Khyatti M; Benider A; Jouhadi H; Kahlain A; Cochet C; Mansouri A; El Gueddari B; Benslimane A; Joab I
Int J Cancer; 2000 Apr; 86(1):71-5. PubMed ID: 10728597
[TBL] [Abstract][Full Text] [Related]
18. [IgG- and IgA-antibodies to the Epstein-Barr virus in the sera of patients with nasopharyngeal carcinoma in Cuba].
Gurtsevich VE; Ruíz García R; Cuevas J; Le Riverand Morales E; Ascue M
Vopr Virusol; 1979; (4):392-9. PubMed ID: 225887
[TBL] [Abstract][Full Text] [Related]
19. Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study - a review.
de-Thé G; Day NE; Geser A; Lavoué MF; Ho JH; Simons MJ; Sohier R; Tukei P; Vonka V; Zavadova H
IARC Sci Publ (1971); 1975; (11 Pt 2):3-16. PubMed ID: 191375
[TBL] [Abstract][Full Text] [Related]
20. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
